Final Phase IIb Interferon-Free Hepatitis C Data From Boehringer Ingelheim Corporation to be Presented at AASLD

INGELHEIM, Germany--(BUSINESS WIRE)--New data from Boehringer Ingelheim’s hepatitis C virus (HCV) clinical development programme, HCVersoTM, have been accepted for presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 9 – 13 November in Boston, MA. Seven abstracts will be presented at the meeting, most notably final results from the Phase IIb interferon-free SOUND-C2 trial of faldaprevir (formerly known as BI 201335) and BI 207127 with and without ribavirin.1,2 This study includes patients with the most common and most challenging type of HCV to cure, genotype-1, including patients with complete liver cirrhosis,1 an advanced form of liver disease.